Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 26;13(1):2956.
doi: 10.1038/s41467-022-30580-5.

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

Affiliations

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

Jing Zou et al. Nat Commun. .

Abstract

The Omicron SARS-CoV-2 has several distinct sublineages, among which sublineage BA.1 is responsible for the initial Omicron surge and is now being replaced by BA.2 worldwide, whereas BA.3 is currently at a low frequency. The ongoing BA.1-to-BA.2 replacement underscores the importance to understand the cross-neutralization among the three Omicron sublineages. Here we test the neutralization of BA.1-infected human sera against BA.2, BA.3, and USA/WA1-2020 (a strain isolated in late January 2020). The BA.1-infected sera neutralize BA.1, BA.2, BA.3, and USA/WA1-2020 SARS-CoV-2s with geometric mean titers (GMTs) of 445, 107, 102, and 16, respectively. Thus, the neutralizing GMTs against heterologous BA.2, BA.3, and USA/WA1-2020 are 4.2-, 4.4-, and 28.4-fold lower than the GMT against homologous BA.1, respectively. These findings have implications in COVID-19 vaccine strategy.

PubMed Disclaimer

Conflict of interest statement

X.X. and P.-Y.S. have filed a patent on the reverse genetic system. J.Z., C.K., X.X., and P.-Y.S. received compensation from Pfizer for COVID-19 vaccine development. Other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Cross-neutralization of human sera from unvaccinated individuals who were infected with Omicron BA.1 SARS-CoV-2.
A Omicron BA.1-, BA.2-, and BA.3-spike mNG SARS-CoV-2s. The full-length spike gene from Omicron BA.1, BA.2, or BA.3 was engineered into an mNG USA-WA1/2020 SARS-CoV-2. The mNG gene was engineered at the open-reading-frame-7 of the viral genome. Amino acid mutations, deletions, and insertions (Ins) are indicated for BA.1, BA.2, and BA.3 spikes in reference to the USA-WA1/2020 spike. L leader sequence, ORF open reading frame, NTD N-terminal domain of S1, RBD receptor binding domain of S1, S spike glycoprotein, S1 N-terminal furin cleavage fragment of S, S2 C-terminal furin cleavage fragment of S, E envelope protein, M membrane protein, N nucleoprotein, UTR untranslated region. B Scatterplot of neutralization titers. A panel of 20 human sera collected from Omicron BA.1-infected individuals were tested for the 50% fluorescent focus-reduction neutralization titers (FFRNT50) against recombinant USA-WA1/2020 (gray circles), Omicron BA.1- (blue circles), BA.2- (green circles), and BA.3-spike (red circels) mNG SARS-CoV-2s. The neutralization titer for each virus was determined in duplicates. The serum information and FFRNT50 values are summarized in Table 1. Each data point represents the geometric mean FFRNT50 obtained with a serum specimen against the indicated virus. The bar heights and the numbers above indicate geometric mean titers (GMTs). Error bars indicate the 95% confidence interval (CI) of the GMTs. Data are presented as GMT with 95% CI. Statistical analysis was performed using the Wilcoxon matched-pairs signed-rank test. Two-tailed P values of the GMT against BA.1-spike and USA-WA1/2020, BA.2-spike, or BA.3 spikes are all <0.0001. C FFRNT50 values with connected lines for individual sera. Two sera exhibiting slightly higher FFRNT50s against BA.2 virus than that against BA.1-spike SARS-CoV-2 are indicated by symbol asterisk (serum ID 1 and 2 in Table 1).

Similar articles

Cited by

References

    1. Wolter N, et al. Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa. MedRxiv. 2022 doi: 10.1101/2022.02.17.22271030. - DOI - PMC - PubMed
    1. Lyngse FP, et al. Transmission of SARS-CoV-2 omicron VOC subvariants BA.1 and BA.2: evidence from danish households. BioRxiv. 2022 doi: 10.1101/2022.01.28.22270044. - DOI
    1. Xia H, et al. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host Microbe. 2022 doi: 10.1016/j.chom.2022.02.015. - DOI - PMC - PubMed
    1. Kurhade, C. et al. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. BioRxivhttps://biorxiv.org/cgi/content/short/2022.2003.2024.485633v485631 (2022).
    1. Zou J, et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat. Commun. 2022;13:852. doi: 10.1038/s41467-022-28544-w. - DOI - PMC - PubMed

Publication types